Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 5,277 matching trials from the live ClinicalTrials.gov search.

Filters: Gainesville, Florida Clear all

Conditions: Angina
Interventions: Ranolazine, Sugar pill; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: ED Patients With Chronic Medical Illnesses
Interventions: ED-to-home care transition intervention, Usual Care; Behavioral · Other
Lead sponsor: University of Florida; Other
Eligibility: 60 Years and older
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell
Interventions: Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine; Drug · Combination Product
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Gainesville, Florida

Conditions: Obesity, Sarcopenia
Interventions: Lifestyle Counseling, Educational Control; Behavioral · Other
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 79 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pain
Interventions: CYP2D6 genotyping, Pain assessment questionnaire, Physician assessment; Genetic · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Archer, Florida • Gainesville, Florida • Old Town, Florida + 2 more

Conditions: Subjective Cognitive Decline (SCD), Healthy Subjects
Interventions: Experimental -- 16.67 Hz Visual Occlusion, Control - 1Hz Visual Occlusion; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Musculoskeletal Pain
Interventions: Delayed onset muscle soreness.; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Intracranial Vascular Disorders
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 99 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Chronic Hepatitis C
Interventions: PSI-7977, Daclatasvir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Coronado, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions: Jelmyto (mitomycin) for pyelocalyceal solution; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 22
States / cities: Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more

Conditions: Cystic Fibrosis
Interventions: Inhaled AR-501, Inhaled Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more

Conditions: Cutaneous Squamous Cell Carcinoma
Interventions: Cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 40
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Necrotizing Enterocolitis, Intra-abdominal Infection
Interventions: meropenem; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: Up to 90 Days
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Oakland, California • Orange, California + 21 more

Conditions: Non-Hodgkin's Lymphoma, Follicular Lymphoma
Interventions: Iodine I -01 Tositumomab (Bexxar), External Beam Radiation Therapy; Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Endometrial Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan, Cisplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more

Conditions: Asthma
Interventions: Fluticasone Propionate Formulation 1, Fluticasone Propionate Formulation 2, Fluticasone Propionate Formulation 3*; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Crohn's Disease
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 39
States / cities: Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: ofatumumab + bendamustine; Drug
Lead sponsor: Nevada Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Gainesville, Florida • Las Vegas, Nevada

Conditions: Tourette Syndrome
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Long Beach, California • National City, California • San Bernardino, California + 27 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions: Magnetic Resonance Imaging, Prophylactic Cranial Irradiation; Procedure · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 428
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Choriocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Dysgerminoma, Ovarian Embryonal Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Polyembryoma, Ovarian Sarcoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Stage I Ovarian Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions: Cognitive Assessment, Quality-of-Life Assessment; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 182
States / cities: Tucson, Arizona • Little Rock, Arkansas • Burbank, California + 129 more

Conditions: Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 264
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 206 more

Conditions: Atrial Fibrillation
Interventions: AFSW Guided DOAC, Continuous DOAC therapy; Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 5,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 93
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more

Conditions: Covid19
Interventions: Ivermectin, Placebo; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 93
States / cities: Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 81 more

Search by objective public record fields.

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

Biological Effects of Weight Loss In Older, Obese Women

Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics

High Frequency Stimulation to Improve Cognition, Mobility, and Affect in Individuals With and Without Subjective Cognitive Decline

Mechanisms and Modulation of Pain Modulatory Capacity

Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)